There are growth stories, and then there are compounding machines that make investors wonder if the ink will ever run dry. Intuitive Surgical (ISRG) falls squarely into the latter camp. On Wednesday, the robotic surgery juggernaut unveiled first-quarter results that didn’t just beat expectations—they steamrolled them, sending shares up more than 8% and extending an almost absurd streak: 13 consecutive quarters of double-digit revenue growth.
For a company already valued at a premium that implies near-flawless execution, the report served as a reminder of why the market is willing to pay up. The da Vinci ecosystem isn’t just a product cycle; it’s an annuity dressed in surgical scrubs.
Let’s start with the headline figures, because they’re too good to bury. Revenue climbed 23% year-over-year to $2.77 billion, comfortably ahead of the $2.62 billion consensus. Adjusted earnings per share soared 38% to $2.50, leaving the $2.11 analyst estimate in the dust. But the real story lies beneath the top line—in the mechanics of how Intuitive Surgical actually makes money.
The company’s “razor-and-blade” model is well understood, but it’s worth reiterating just how powerful this flywheel has become. System placements are the entry point; recurring instrument and accessory sales are the perpetual motion. In Q1, global da Vinci procedure volume jumped 17%, while Ion robotic bronchoscopy procedures—a key growth avenue in early lung cancer detection—surged an eye-popping 39%.
As Larry Biegelsen of Wells Fargo noted, “When you see procedure volume jump 17% and instrument sales follow right behind at 23%, you’re witnessing a recurring revenue flywheel that very few hardware companies ever achieve.”
The transition to the next-generation da Vinci 5 platform is proving to be a major catalyst. Of the 431 systems placed during the quarter, 232 were da Vinci 5 units—more than half. That’s a clear signal that hospitals are not just buying robots; they’re actively upgrading to the latest and greatest, which carries higher instrument pull-through and better margins for Intuitive Surgical.
This upgrade cycle is crucial because it resets the installed base at a higher level of efficiency and capability. And with the company recently securing FDA 510(k) clearance for expanded uses of its Force Feedback instruments, the value proposition for surgeons only gets stronger.
If there’s one number that defines Intuitive Surgical’s investment thesis, it’s this: recurring revenue—instruments, accessories, and services—now accounts for 86% of total revenue. That’s not a typo. Nearly nine out of every ten dollars the company brings in comes from recurring sources, not one-time system sales.
This is the financial equivalent of a fortress. It means that even if hospital capital budgets tighten temporarily, the revenue stream from consumables and service contracts remains largely intact. The model generates so much cash that Intuitive Surgical repurchased $1.1 billion of its own stock in the first quarter alone, retiring about 0.65% of shares outstanding in just three months.
While the U.S. remains the core market, the international opportunity is quietly becoming a significant contributor. Da Vinci procedures outside the United States grew 19% in Q1 and now represent 38% of global volume. Management pointed to expanded reimbursement coverage and favorable policy shifts in Japan and Europe as tailwinds that should continue to support adoption abroad.
That said, not every geography is firing on all cylinders. China presents a more complicated picture, with domestic competition intensifying and policy-driven pricing pressure weighing on the outlook. Japan, too, warrants near-term caution given the financial strains on public hospitals. But for now, the strength in the U.S. and Europe is more than enough to offset these pockets of friction.
Profitability metrics underscore the operating leverage embedded in the business. Adjusted gross margin expanded to 67.8%, up from 66.4% a year ago, while adjusted operating margin reached a robust 39%. Management responded by lifting full-year 2026 guidance for worldwide da Vinci procedure growth to 13.5%–15.5%, up from the prior 13%–15% range. The gross margin outlook was also nudged higher.
After the post-earnings pop, Intuitive Surgical trades at roughly 49 to 51 times forward earnings. That’s a multiple that screams “priced for perfection.” And indeed, any stumble—whether from slowing procedure growth, margin compression, or competitive inroads—could trigger a sharp rerating.
Yet, as Vijay Kumar of Evercore ISI points out, “The multiple certainly reflects expectations of perfection, but the beauty of this story is that it almost always delivers exactly that. That 86% recurring revenue mix makes the premium P/E look far more reasonable than it would for a pure hardware company.”
Amit Hazan of Goldman Sachs zeroes in on Ion as the underappreciated growth engine: “That 39% procedure growth in Ion isn’t just a number—it’s the establishment of a new standard of care in early lung cancer detection that competitors will struggle to match.”
Intuitive Surgical has built something rare in medtech: a business model that combines razor-blade economics with genuine clinical differentiation and a long runway for global adoption. With da Vinci 5 adoption accelerating, Ion carving out a new niche in lung cancer screening, and recurring revenue approaching 90% of the total, the company’s growth narrative remains firmly intact.
Thirteen quarters of double-digit growth is no fluke. It’s the sound of a money printer that shows no signs of jamming.
